Figure 1.

Inhibition of HepG2 human hepatocellular carcinoma cell growth by embelin. Cell viability was assessed using the MTT method after HepG2 cells were treated with different concentrations of embelin (0, 40, 80, 120 and 160 μg/ml) for 24, 48 and 72 h. The results are representative of six independent experiments.